{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:01:16Z","timestamp":1786978876377,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":95,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031297496","type":"print"},{"value":"9783031297502","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-29750-2_15","type":"book-chapter","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T05:02:51Z","timestamp":1689051771000},"page":"199-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical Models of Meningioma"],"prefix":"10.1007","author":[{"given":"Gerhard","family":"Jungwirth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Oliver","family":"Hanemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"2","key":"15_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11060-005-9076-y","volume":"78","author":"GS Baia","year":"2006","unstructured":"Baia GS, Slocum AL, Hyer JD, et al. A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neurooncol. 2006;78(2):113\u2013121. doi:https:\/\/doi.org\/10.1007\/s11060-005-9076-y","journal-title":"J Neurooncol."},{"issue":"4","key":"15_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-04-0786","volume":"65","author":"VK Puduvalli","year":"2005","unstructured":"Puduvalli VK, Li JT, Chen L, McCutcheon IE. Induction of Apoptosis in Primary Meningioma Cultures by Fenretinide. Cancer Res. 2005;65(4):1547\u20131553. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0786","journal-title":"Cancer Res."},{"issue":"4","key":"15_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3171\/jns.1945.2.4.0315","volume":"2","author":"HSN Greene","year":"1945","unstructured":"Greene HSN, Arnold H. The Homologous and Heterologous Transplantation of Brain and Brain Tumors. J Neurosurg. 1945;2(4):315\u2013331. doi:https:\/\/doi.org\/10.3171\/jns.1945.2.4.0315","journal-title":"J Neurosurg."},{"issue":"1","key":"15_CR4","first-page":"110","volume":"36","author":"M Klagsbrun","year":"1976","unstructured":"Klagsbrun M, Knighton D, Folkman J. Tumor angiogenesis activity in cells grown in tissue culture. Cancer Res. 1976;36(1):110\u2013114.","journal-title":"Cancer Res."},{"issue":"3","key":"15_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ijc.2910150306","volume":"15","author":"HB Vogel","year":"1975","unstructured":"Vogel HB, Berry RG. Chorioallantoic membrane heterotransplantation of human brain tumors. Int J Cancer. 1975;15(3):401\u2013408. doi:https:\/\/doi.org\/10.1002\/ijc.2910150306","journal-title":"Int J Cancer."},{"issue":"2","key":"15_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.nbd.2007.09.002","volume":"29","author":"MF James","year":"2008","unstructured":"James MF, Lelke JM, Maccollin M, et al. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008;29(2):278\u2013292. doi:https:\/\/doi.org\/10.1016\/j.nbd.2007.09.002","journal-title":"Neurobiol Dis."},{"issue":"18","key":"15_CR7","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","volume":"77","author":"DS Stepanova","year":"2017","unstructured":"Stepanova DS, Semenova G, Kuo Y-M, et al. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res. 2017;77(18):5026\u20135038. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2834","journal-title":"Cancer Res."},{"issue":"1","key":"15_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa008","volume":"2","author":"S Ferluga","year":"2020","unstructured":"Ferluga S, Baiz D, Hilton DA, et al. Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells. Neuro-Oncol Adv. 2020;2(1):vdaa008. doi:https:\/\/doi.org\/10.1093\/noajnl\/vdaa008","journal-title":"Neuro-Oncol Adv."},{"issue":"3","key":"15_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","volume":"27","author":"WH Lee","year":"1990","unstructured":"Lee WH. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery. 1990;27(3):389\u2013395; discussion 396.","journal-title":"Neurosurgery."},{"issue":"11","key":"15_CR10","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S","volume":"64","author":"K Tanaka","year":"1989","unstructured":"Tanaka K, Sato C, Maeda Y, et al. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer. 1989;64(11):2243\u20132249","journal-title":"Cancer."},{"issue":"5","key":"15_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3171\/jns.1995.82.5.0864","volume":"82","author":"JC Tsai","year":"1995","unstructured":"Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82(5):864\u2013873. doi:https:\/\/doi.org\/10.3171\/jns.1995.82.5.0864","journal-title":"J Neurosurg."},{"issue":"1","key":"15_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF01058456","volume":"23","author":"T Yazaki","year":"1995","unstructured":"Yazaki T, Takamiya Y, Costello PC, et al. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol. 1995;23(1):23\u201329. doi:https:\/\/doi.org\/10.1007\/BF01058456","journal-title":"J Neurooncol."},{"issue":"4","key":"15_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00401-003-0736-8","volume":"106","author":"K Akat","year":"2003","unstructured":"Akat K, Mennel H-D, Kremer P, Gassler N, Bleck CKE, Kartenbeck J. Molecular characterization of desmosomes in meningiomas and arachnoidal tissue. Acta Neuropathol (Berl). 2003;106(4):337\u2013347. doi:https:\/\/doi.org\/10.1007\/s00401-003-0736-8","journal-title":"Acta Neuropathol (Berl)."},{"issue":"4","key":"15_CR14","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.18632\/oncotarget.2810","volume":"6","author":"H-Y Chow","year":"2015","unstructured":"Chow H-Y, Dong B, Duron SG, et al. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 2015;6(4):1981\u20131994. doi:https:\/\/doi.org\/10.18632\/oncotarget.2810","journal-title":"Oncotarget."},{"issue":"Suppl 1","key":"15_CR15","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.21037\/cco.2017.05.03","volume":"6","author":"C Mawrin","year":"2017","unstructured":"Mawrin C. Animal models of meningiomas. Chin Clin Oncol. 2017;6(Suppl 1):S6. doi:https:\/\/doi.org\/10.21037\/cco.2017.05.03","journal-title":"Chin Clin Oncol."},{"issue":"3","key":"15_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.surneu.2007.06.031","volume":"70","author":"BT Ragel","year":"2008","unstructured":"Ragel BT, Couldwell WT, Gillespie DL, Wendland MM, Whang K, Jensen RL. A comparison of the cell lines used in meningioma research. Surg Neurol. 2008;70(3):295\u2013307; discussion 307. doi:https:\/\/doi.org\/10.1016\/j.surneu.2007.06.031","journal-title":"Surg Neurol."},{"issue":"2","key":"15_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1750-3639.2007.00109.x","volume":"18","author":"GS Baia","year":"2008","unstructured":"Baia GS, Dinca EB, Ozawa T, et al. An orthotopic skull base model of malignant meningioma. Brain Pathol Zurich Switz. 2008;18(2):172\u2013179. doi:https:\/\/doi.org\/10.1111\/j.1750-3639.2007.00109.x","journal-title":"Brain Pathol Zurich Switz."},{"issue":"5","key":"15_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178322","volume":"12","author":"Y Mei","year":"2017","unstructured":"Mei Y, Bi WL, Greenwald NF, et al. Genomic profile of human meningioma cell lines. PloS One. 2017;12(5):e0178322. doi:https:\/\/doi.org\/10.1371\/journal.pone.0178322","journal-title":"PloS One."},{"issue":"3","key":"15_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/2015.6.JNS15591","volume":"125","author":"WL Bi","year":"2016","unstructured":"Bi WL, Abedalthagafi M, Horowitz P, et al. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016;125(3):525\u2013535. doi:https:\/\/doi.org\/10.3171\/2015.6.JNS15591","journal-title":"J Neurosurg."},{"issue":"2","key":"15_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","volume":"159","author":"J Bostr\u00f6m","year":"2001","unstructured":"Bostr\u00f6m J, Meyer-Puttlitz B, Wolter M, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol. 2001;159(2):661\u2013669. doi:https:\/\/doi.org\/10.1016\/S0002-9440(10)61737-3","journal-title":"Am J Pathol."},{"issue":"2","key":"15_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3171\/JNS\/2008\/108\/2\/0304","volume":"108","author":"BT Ragel","year":"2008","unstructured":"Ragel BT, Elam IL, Gillespie DL, et al. A novel model of intracranial meningioma in mice using luciferase-expressing meningioma cells. Laboratory investigation. J Neurosurg. 2008;108(2):304\u2013310. doi:https:\/\/doi.org\/10.3171\/JNS\/2008\/108\/2\/0304","journal-title":"J Neurosurg."},{"issue":"2","key":"15_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3171\/jns.2000.92.2.0306","volume":"92","author":"IE McCutcheon","year":"2000","unstructured":"McCutcheon IE, Friend KE, Gerdes TM, Zhang B-M, Wildrick DM, Fuller GN. Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg. 2000;92(2):306\u2013314. doi:https:\/\/doi.org\/10.3171\/jns.2000.92.2.0306","journal-title":"J Neurosurg."},{"issue":"1","key":"15_CR23","first-page":"5","volume":"31","author":"P Tummalapalli","year":"2007","unstructured":"Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol. 2007;31(1):5\u201317.","journal-title":"Int J Oncol."},{"issue":"6","key":"15_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/neuonc\/not007","volume":"15","author":"K Iwami","year":"2013","unstructured":"Iwami K, Natsume A, Ohno M, et al. Adoptive transfer of genetically modified Wilms\u2019 tumor 1-specific T cells in a novel malignant skull base meningioma model. Neuro-Oncol. 2013;15(6):747\u2013758. doi:https:\/\/doi.org\/10.1093\/neuonc\/not007","journal-title":"Neuro-Oncol."},{"key":"15_CR25","doi-asserted-by":"publisher","unstructured":"Jungwirth G, Yu T, Moustafa M, et al. Identification of KIF11 As a Novel Target in Meningioma. Cancers. 2019;11(4). doi:https:\/\/doi.org\/10.3390\/cancers11040545","DOI":"10.3390\/cancers11040545"},{"issue":"9","key":"15_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/labinvest.3700307","volume":"85","author":"S P\u00fcttmann","year":"2005","unstructured":"P\u00fcttmann S, Senner V, Braune S, et al. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Investig J Tech Methods Pathol. 2005;85(9):1163\u20131171. doi:https:\/\/doi.org\/10.1038\/labinvest.3700307","journal-title":"Lab Investig J Tech Methods Pathol."},{"issue":"6","key":"15_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3892\/ijmm.12.6.943","volume":"12","author":"L Boldrini","year":"2003","unstructured":"Boldrini L, Pistolesi S, Gisfredi S, et al. Telomerase in intracranial meningiomas. Int J Mol Med. 2003;12(6):943\u2013947. doi:https:\/\/doi.org\/10.3892\/ijmm.12.6.943","journal-title":"Int J Mol Med."},{"issue":"5","key":"15_CR28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3171\/jns.2000.92.5.0832","volume":"92","author":"M Simon","year":"2000","unstructured":"Simon M, Park TW, Leuenroth S, Hans VH, L\u00f6ning T, Schramm J. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J Neurosurg. 2000;92(5):832\u2013840. doi:https:\/\/doi.org\/10.3171\/jns.2000.92.5.0832","journal-title":"J Neurosurg."},{"issue":"4","key":"15_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0046-8177(97)90029-0","volume":"28","author":"LA Langford","year":"1997","unstructured":"Langford LA, Piatyszek MA, Xu R, Schold SC, Wright WE, Shay JW. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol. 1997;28(4):416\u2013420. doi:https:\/\/doi.org\/10.1016\/S0046-8177(97)90029-0","journal-title":"Hum Pathol."},{"issue":"10","key":"15_CR30","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/1097-0142(20001115)89:10<2092::AID-CNCR9>3.0.CO;2-N","volume":"89","author":"H-J Chen","year":"2000","unstructured":"Chen H-J, Liang C-L, Lu K, Lin J-W, Cho C-L. Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer. 2000;89(10):2092\u20132098","journal-title":"Cancer."},{"key":"15_CR31","doi-asserted-by":"publisher","unstructured":"Sahm F, Schrimpf D, Olar A, et al. TERT Promoter Mutations and Risk of Recurrence in Meningioma. J Natl Cancer Inst. 2016;108(5). doi:https:\/\/doi.org\/10.1093\/jnci\/djv377","DOI":"10.1093\/jnci\/djv377"},{"issue":"12","key":"15_CR32","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","volume":"20","author":"S Spiegl-Kreinecker","year":"2018","unstructured":"Spiegl-Kreinecker S, L\u00f6tsch D, Neumayer K, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro-Oncol. 2018;20(12):1584\u20131593. doi:https:\/\/doi.org\/10.1093\/neuonc\/noy104","journal-title":"Neuro-Oncol."},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12967-015-0596-8","volume":"13","author":"SK Michelhaugh","year":"2015","unstructured":"Michelhaugh SK, Guastella AR, Varadarajan K, et al. Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1. J Transl Med. 2015;13:227. doi:https:\/\/doi.org\/10.1186\/s12967-015-0596-8","journal-title":"J Transl Med."},{"issue":"4","key":"15_CR34","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1227\/01.NEU.0000255397.00410.8F","volume":"60","author":"TG Cargioli","year":"2007","unstructured":"Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS. Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery. 2007;60(4):750\u2013759; discussion 759\u2013760. doi:https:\/\/doi.org\/10.1227\/01.NEU.0000255397.00410.8F","journal-title":"Neurosurgery."},{"issue":"2","key":"15_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00441-007-0512-5","volume":"331","author":"K Akat","year":"2008","unstructured":"Akat K, Bleck CKE, Lee Y-MA, Haselmann-Weiss U, Kartenbeck J. Characterization of a novel type of adherens junction in meningiomas and the derived cell line HBL-52. Cell Tissue Res. 2008;331(2):401\u2013412. doi:https:\/\/doi.org\/10.1007\/s00441-007-0512-5","journal-title":"Cell Tissue Res."},{"issue":"10 Suppl","key":"15_CR36","first-page":"2386","volume":"53","author":"SA Rempel","year":"1993","unstructured":"Rempel SA, Schwechheimer K, Davis RL, Cavenee WK, Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res. 1993;53(10 Suppl):2386\u20132392.","journal-title":"Cancer Res."},{"issue":"7","key":"15_CR37","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1541-7786.MCR-12-0116","volume":"10","author":"GS Baia","year":"2012","unstructured":"Baia GS, Caballero OL, Orr BA, et al. Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res MCR. 2012;10(7):904\u2013913. doi:https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0116","journal-title":"Mol Cancer Res MCR."},{"issue":"11","key":"15_CR38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1593\/neo.08642","volume":"10","author":"K Striedinger","year":"2008","unstructured":"Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The Neurofibromatosis 2 Tumor Suppressor Gene Product, Merlin, Regulates Human Meningioma Cell Growth by Signaling through YAP. Neoplasia N Y N. 2008;10(11):1204\u20131212.","journal-title":"Neoplasia N Y N."},{"issue":"5","key":"15_CR39","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","volume":"19","author":"D Pachow","year":"2013","unstructured":"Pachow D, Andrae N, Kliese N, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(5):1180\u20131189. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1904","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"4","key":"15_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1749-0774.2004.tb00045.x","volume":"17","author":"I Ishiwata","year":"2004","unstructured":"Ishiwata I, Ishiwata C, Ishiwata E, et al. In vitro culture of various typed meningiomas and characterization of a human malignant meningioma cell line (HKBMM). Hum Cell. 2004;17(4):211\u2013217. doi:https:\/\/doi.org\/10.1111\/j.1749-0774.2004.tb00045.x","journal-title":"Hum Cell."},{"issue":"53","key":"15_CR41","doi-asserted-by":"publisher","first-page":"90996","DOI":"10.18632\/oncotarget.18827","volume":"8","author":"H Takeda","year":"2017","unstructured":"Takeda H, Okada M, Kuramoto K, et al. Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo. Oncotarget. 2017;8(53):90996\u201391008. doi:https:\/\/doi.org\/10.18632\/oncotarget.18827","journal-title":"Oncotarget."},{"issue":"7","key":"15_CR42","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/NEN.0000000000000211","volume":"74","author":"K Tanahashi","year":"2015","unstructured":"Tanahashi K, Natsume A, Ohka F, et al. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness. J Neuropathol Exp Neurol. 2015;74(7):704\u2013709. doi:https:\/\/doi.org\/10.1097\/NEN.0000000000000211","journal-title":"J Neuropathol Exp Neurol."},{"issue":"21","key":"15_CR43","first-page":"4752","volume":"55","author":"T Yazaki","year":"1995","unstructured":"Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995;55(21):4752\u20134756.","journal-title":"Cancer Res."},{"issue":"6123","key":"15_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077\u20131080. doi:https:\/\/doi.org\/10.1126\/science.1233009","journal-title":"Science."},{"issue":"10","key":"15_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE, Harmanc\u0131 AS, Bai H, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016;48(10):1253\u20131259. doi:https:\/\/doi.org\/10.1038\/ng.3651","journal-title":"Nat Genet."},{"issue":"4","key":"15_CR46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/neuonc\/now235","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Abedalthagafi M, Vaubel RA, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncol. 2017;19(4):535\u2013545. doi:https:\/\/doi.org\/10.1093\/neuonc\/now235","journal-title":"Neuro-Oncol."},{"issue":"1","key":"15_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40478-019-0793-4","volume":"7","author":"G Jungwirth","year":"2019","unstructured":"Jungwirth G, Warta R, Beynon C, et al. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol Commun. 2019;7(1):140. doi:https:\/\/doi.org\/10.1186\/s40478-019-0793-4","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"15_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ng.2552","volume":"45","author":"MJ Smith","year":"2013","unstructured":"Smith MJ, O\u2019Sullivan J, Bhaskar SS, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013;45(3):295\u2013298. doi:https:\/\/doi.org\/10.1038\/ng.2552","journal-title":"Nat Genet."},{"issue":"5","key":"15_CR49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nov316","volume":"18","author":"M Abedalthagafi","year":"2016","unstructured":"Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncol. 2016;18(5):649\u2013655. doi:https:\/\/doi.org\/10.1093\/neuonc\/nov316","journal-title":"Neuro-Oncol."},{"issue":"3","key":"15_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285\u2013289. doi:https:\/\/doi.org\/10.1038\/ng.2526","journal-title":"Nat Genet."},{"issue":"1","key":"15_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40478-020-00912-x","volume":"8","author":"N von Spreckelsen","year":"2020","unstructured":"von Spreckelsen N, Waldt N, Poetschke R, et al. KLF4K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. Acta Neuropathol Commun. 2020;8(1):41. doi:https:\/\/doi.org\/10.1186\/s40478-020-00912-x","journal-title":"Acta Neuropathol Commun."},{"issue":"4","key":"15_CR52","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3171\/jns.1987.66.4.0584","volume":"66","author":"JJ Olson","year":"1987","unstructured":"Olson JJ, Beck DW, Schlechte JA, Loh PM. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg. 1987;66(4):584\u2013587. doi:https:\/\/doi.org\/10.3171\/jns.1987.66.4.0584","journal-title":"J Neurosurg."},{"issue":"1","key":"15_CR53","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12035-016-9763-z","volume":"54","author":"C Jiang","year":"2017","unstructured":"Jiang C, Song T, Li J, et al. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma. Mol Neurobiol. 2017;54(1):779\u2013787. doi:https:\/\/doi.org\/10.1007\/s12035-016-9763-z","journal-title":"Mol Neurobiol."},{"issue":"4","key":"15_CR54","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3171\/jns.1989.71.4.0545","volume":"71","author":"A Medhkour","year":"1989","unstructured":"Medhkour A, Van Roey M, Sobel RA, Fingert HJ, Lee J, Martuza RL. Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth. J Neurosurg. 1989;71(4):545\u2013550. doi:https:\/\/doi.org\/10.3171\/jns.1989.71.4.0545","journal-title":"J Neurosurg."},{"issue":"4","key":"15_CR55","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/FOC-07\/10\/E10","volume":"23","author":"BT Ragel","year":"2007","unstructured":"Ragel BT, Couldwell WT, Wurster RD, Jensen RL. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus. 2007;23(4):E10. doi:https:\/\/doi.org\/10.3171\/FOC-07\/10\/E10","journal-title":"Neurosurg Focus."},{"issue":"5","key":"15_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0090-3019(01)00444-X","volume":"55","author":"RL Jensen","year":"2001","unstructured":"Jensen RL, Wurster RD. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surg Neurol. 2001;55(5):275\u2013283. doi:https:\/\/doi.org\/10.1016\/S0090-3019(01)00444-X","journal-title":"Surg Neurol."},{"issue":"3","key":"15_CR57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3171\/jns.2001.94.3.0487","volume":"94","author":"IE McCutcheon","year":"2001","unstructured":"McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001;94(3):487\u2013492. doi:https:\/\/doi.org\/10.3171\/jns.2001.94.3.0487","journal-title":"J Neurosurg."},{"issue":"3","key":"15_CR58","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3171\/jns.2007.106.3.455","volume":"106","author":"V Gupta","year":"2007","unstructured":"Gupta V, Su YS, Samuelson CG, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106(3):455\u2013462. doi:https:\/\/doi.org\/10.3171\/jns.2007.106.3.455","journal-title":"J Neurosurg."},{"key":"15_CR59","doi-asserted-by":"publisher","unstructured":"Yu T, Cao J, Eddine MA, et al. Receptor-tyrosine kinase inhibitor ponatinib inhibits meningioma growth in vitro and in vivo. Cancers. 2021;13(23):5898. doi:https:\/\/doi.org\/10.3390\/cancers13235898","DOI":"10.3390\/cancers13235898"},{"issue":"4","key":"15_CR60","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3171\/FOC-07\/10\/E9","volume":"23","author":"V Gupta","year":"2007","unstructured":"Gupta V, Samuleson CG, Su S, Chen TC. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus. 2007;23(4):E9. doi:https:\/\/doi.org\/10.3171\/FOC-07\/10\/E9","journal-title":"Neurosurg Focus."},{"issue":"4","key":"15_CR61","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/FOC-07\/10\/E7","volume":"23","author":"BT Ragel","year":"2007","unstructured":"Ragel BT, Jensen RL, Couldwell WT. Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Neurosurg Focus. 2007;23(4):E7. doi:https:\/\/doi.org\/10.3171\/FOC-07\/10\/E7","journal-title":"Neurosurg Focus."},{"key":"15_CR62","doi-asserted-by":"publisher","unstructured":"Jungwirth G, Yu T, Cao J, et al. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Lett. 2021;506:1\u201310. doi:https:\/\/doi.org\/10.1016\/j.canlet.2021.02.016","DOI":"10.1016\/j.canlet.2021.02.016"},{"issue":"19","key":"15_CR63","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1158\/1078-0432.CCR-12-0299","volume":"19","author":"A Wilisch-Neumann","year":"2013","unstructured":"Wilisch-Neumann A, Kliese N, Pachow D, et al. The integrin inhibitor cilengitide affects meningioma cell motility and invasion. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(19):5402\u20135412. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0299","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"15_CR64","doi-asserted-by":"publisher","unstructured":"Giles AJ, Hao S, Padget M, et al. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight. 4(20). doi:https:\/\/doi.org\/10.1172\/jci.insight.130688","DOI":"10.1172\/jci.insight.130688"},{"key":"15_CR65","doi-asserted-by":"publisher","unstructured":"Jungwirth G, Yu T, Liu F, et al. Pharmacological landscape of FDA-approved anticancer drugs reveals sensitivities to iabepilone romidepsin omacetaxine and carfilzomib in aggressive meningiomas. Abtract. Clin Cancer Res. 2023;29(1):233\u2013243. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2085","DOI":"10.1158\/1078-0432.CCR-22-2085"},{"issue":"5","key":"15_CR66","first-page":"937","volume":"33","author":"O Kargiotis","year":"2008","unstructured":"Kargiotis O, Chetty C, Gogineni V, et al. uPA\/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol. 2008;33(5):937\u2013947.","journal-title":"Int J Oncol."},{"issue":"3","key":"15_CR67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ilar\/ily026","volume":"59","author":"E Radaelli","year":"2018","unstructured":"Radaelli E, Santagostino SF, Sellers RS, Brayton CF. Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research. ILAR J. 2018;59(3):211\u2013246. doi:https:\/\/doi.org\/10.1093\/ilar\/ily026","journal-title":"ILAR J."},{"key":"15_CR68","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026781","volume-title":"Tumor Microenvironment and Differential Responses to Therapy","author":"E Hirata","year":"2017","unstructured":"Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med. 2017;7(7). doi:https:\/\/doi.org\/10.1101\/cshperspect.a026781"},{"issue":"1","key":"15_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ame2.12050","volume":"2","author":"F La Cava","year":"2019","unstructured":"La Cava F, Fringuello Mingo A, Irrera P, et al. Orthotopic induction of CH157MN convexity and skull base meningiomas into nude mice using stereotactic surgery and MRI characterization. Anim Models Exp Med. 2019;2(1):58\u201363. doi:https:\/\/doi.org\/10.1002\/ame2.12050","journal-title":"Anim Models Exp Med."},{"issue":"3","key":"15_CR70","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11060-018-03009-7","volume":"140","author":"CG Skibinski","year":"2018","unstructured":"Skibinski CG, Williamson T, Riggins G. Mebendazole and Radiation in Combination Increase Survival through Anticancer Mechanisms in an Intracranial Rodent Model of Malignant Meningioma. J Neurooncol. 2018;140(3):529\u2013538. doi:https:\/\/doi.org\/10.1007\/s11060-018-03009-7","journal-title":"J Neurooncol."},{"issue":"2","key":"15_CR71","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/0008-5472.CAN-12-1888","volume":"73","author":"SS Burns","year":"2013","unstructured":"Burns SS, Akhmametyeva EM, Oblinger JL, et al. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res. 2013;73(2):792\u2013803. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1888","journal-title":"Cancer Res."},{"issue":"36","key":"15_CR72","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/onc.2012.436","volume":"32","author":"M Peyre","year":"2013","unstructured":"Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, et al. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene. 2013;32(36):4264\u20134272. doi:https:\/\/doi.org\/10.1038\/onc.2012.436","journal-title":"Oncogene."},{"issue":"73","key":"15_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2016.12.004","volume":"2017","author":"M Tuchen","year":"1990","unstructured":"Tuchen M, Wilisch-Neumann A, Daniel EA, et al. Receptor tyrosine kinase inhibition by regorafenib\/sorafenib inhibits growth and invasion of meningioma cells. Eur J Cancer Oxf Engl 1990. 2017;73:9\u201321. doi:https:\/\/doi.org\/10.1016\/j.ejca.2016.12.004","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"9","key":"15_CR74","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","volume":"20","author":"SP Angus","year":"2018","unstructured":"Angus SP, Oblinger JL, Stuhlmiller TJ, et al. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncol. 2018;20(9):1185\u20131196. doi:https:\/\/doi.org\/10.1093\/neuonc\/noy046","journal-title":"Neuro-Oncol."},{"key":"15_CR75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","volume":"86","author":"M Karsy","year":"2016","unstructured":"Karsy M, Hoang N, Barth T, et al. Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. World Neurosurg. 2016;86:210\u2013219. doi:https:\/\/doi.org\/10.1016\/j.wneu.2015.09.060","journal-title":"World Neurosurg."},{"issue":"5","key":"15_CR76","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.3892\/ol.2017.6832","volume":"14","author":"O B\u00e4hr","year":"2017","unstructured":"B\u00e4hr O, Gross S, Harter PN, et al. ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. Oncol Lett. 2017;14(5):5443\u20135451. doi:https:\/\/doi.org\/10.3892\/ol.2017.6832","journal-title":"Oncol Lett."},{"issue":"Supplement_1","key":"15_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy136","volume":"21","author":"PK Brastianos","year":"2019","unstructured":"Brastianos PK, Galanis E, Butowski N, et al. Advances in multidisciplinary therapy for meningiomas. Neuro-Oncol. 2019;21(Supplement_1):i18\u2013i31. doi:https:\/\/doi.org\/10.1093\/neuonc\/noy136","journal-title":"Neuro-Oncol."},{"issue":"17","key":"15_CR78","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","volume":"25","author":"C Rapp","year":"2019","unstructured":"Rapp C, Dettling S, Liu F, et al. Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(17):5260\u20135270. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0389","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"9","key":"15_CR79","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"M Kalamarides","year":"2002","unstructured":"Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002;16(9):1060\u20131065. doi:https:\/\/doi.org\/10.1101\/gad.226302","journal-title":"Genes Dev."},{"issue":"10","key":"15_CR80","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1101\/gad.11.10.1253","volume":"11","author":"AI McClatchey","year":"1997","unstructured":"McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 1997;11(10):1253\u20131265. doi:https:\/\/doi.org\/10.1101\/gad.11.10.1253","journal-title":"Genes Dev."},{"issue":"8","key":"15_CR81","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1101\/gad.12.8.1121","volume":"12","author":"AI McClatchey","year":"1998","unstructured":"McClatchey AI, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998;12(8):1121\u20131133. doi:https:\/\/doi.org\/10.1101\/gad.12.8.1121","journal-title":"Genes Dev."},{"issue":"32","key":"15_CR82","doi-asserted-by":"publisher","first-page":"32713","DOI":"10.18632\/oncotarget.5296","volume":"6","author":"M Peyre","year":"2015","unstructured":"Peyre M, Salaud C, Clermont-Taranchon E, et al. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget. 2015;6(32):32713\u201332722. doi:https:\/\/doi.org\/10.18632\/oncotarget.5296","journal-title":"Oncotarget."},{"issue":"1","key":"15_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12964-018-0220-7","volume":"16","author":"GB Carballo","year":"2018","unstructured":"Carballo GB, Honorato JR, de Lopes GPF, Spohr TCL de SE. A highlight on Sonic hedgehog pathway. Cell Commun Signal CCS. 2018;16(1):11. doi:https:\/\/doi.org\/10.1186\/s12964-018-0220-7","journal-title":"Cell Commun Signal CCS."},{"issue":"3","key":"15_CR84","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/neuonc\/now276","volume":"19","author":"J Boetto","year":"2017","unstructured":"Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro-Oncol. 2017;19(3):345\u2013351. doi:https:\/\/doi.org\/10.1093\/neuonc\/now276","journal-title":"Neuro-Oncol."},{"issue":"36","key":"15_CR85","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1038\/s41388-018-0328-7","volume":"37","author":"J Boetto","year":"2018","unstructured":"Boetto J, Apra C, Bielle F, Peyre M, Kalamarides M. Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. Oncogene. 2018;37(36):4955\u20134963. doi:https:\/\/doi.org\/10.1038\/s41388-018-0328-7","journal-title":"Oncogene."},{"key":"15_CR86","unstructured":"Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas \u2013 Full Text View \u2013 ClinicalTrials.gov. Accessed September 22, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02523014"},{"issue":"15","key":"15_CR87","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019101654","volume":"38","author":"M Bleijs","year":"2019","unstructured":"Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in cancer research. EMBO J. 2019;38(15):e101654. doi:https:\/\/doi.org\/10.15252\/embj.2019101654","journal-title":"EMBO J."},{"issue":"2","key":"15_CR88","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0003","volume":"3","author":"TG Meijer","year":"2017","unstructured":"Meijer TG, Naipal KA, Jager A, van Gent DC. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci OA. 2017;3(2):FSO190. doi:https:\/\/doi.org\/10.4155\/fsoa-2017-0003","journal-title":"Future Sci OA."},{"issue":"18","key":"15_CR89","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1073\/pnas.0907676107","volume":"107","author":"V Vaira","year":"2010","unstructured":"Vaira V, Fedele G, Pyne S, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010;107(18):8352\u20138356. doi:https:\/\/doi.org\/10.1073\/pnas.0907676107","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"12","key":"15_CR90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1670019","volume":"8","author":"R Sivakumar","year":"2019","unstructured":"Sivakumar R, Chan M, Shin JS, et al. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019;8(12):e1670019. doi:https:\/\/doi.org\/10.1080\/2162402X.2019.1670019","journal-title":"Oncoimmunology."},{"issue":"2","key":"15_CR91","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2013.700","volume":"110","author":"MM Gerlach","year":"2014","unstructured":"Gerlach MM, Merz F, Wichmann G, et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2014;110(2):479\u2013488. doi:https:\/\/doi.org\/10.1038\/bjc.2013.700","journal-title":"Br J Cancer."},{"issue":"3","key":"15_CR92","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/jclinpath-2012-201147","volume":"66","author":"DL Holliday","year":"2013","unstructured":"Holliday DL, Moss MA, Pollock S, et al. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol. 2013;66(3):253\u2013255. doi:https:\/\/doi.org\/10.1136\/jclinpath-2012-201147","journal-title":"J Clin Pathol."},{"issue":"8","key":"15_CR93","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","volume":"21","author":"M Boretto","year":"2019","unstructured":"Boretto M, Maenhoudt N, Luo X, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019;21(8):1041\u20131051. doi:https:\/\/doi.org\/10.1038\/s41556-019-0360-z","journal-title":"Nat Cell Biol."},{"issue":"1","key":"15_CR94","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY, et al. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. 2020;180(1):188\u2013204.e22. doi:https:\/\/doi.org\/10.1016\/j.cell.2019.11.036","journal-title":"Cell."},{"issue":"5","key":"15_CR95","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41577-019-0248-y","volume":"20","author":"YE Bar-Ephraim","year":"2020","unstructured":"Bar-Ephraim YE, Kretzschmar K, Clevers H. Organoids in immunological research. Nat Rev Immunol. 2020;20(5):279\u2013293. doi:https:\/\/doi.org\/10.1038\/s41577-019-0248-y","journal-title":"Nat Rev Immunol."}],"container-title":["Advances in Experimental Medicine and Biology","Biological and Clinical Landscape of Meningiomas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-29750-2_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T05:05:13Z","timestamp":1689051913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-29750-2_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031297496","9783031297502"],"references-count":95,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-29750-2_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"12 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}